<div id="readability-page-1"><article>Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (&#34;Defence&#34; or the &#34;Company&#34;), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum® platform through both internal development programs and strategic partnerships. Designed to unlock the full potential of complex cancer biologics, Accum® enhances intracellular delivery to increase therapeutic potency while reducing toxicity.At the center of this strategy is Accum®, Defence Therapeutics' proprietary precision drug-delivery platform designed to solve one of oncology's most persistent challenges: effective intracellular delivery. By enhancing cellular uptake and payload release, Accum® increases therapeutic potency at lower doses, with the potential to reduce toxicity and improve patient access to advanced cancer treatments.Defence is prioritizing this platform and partnering model through a dual strategy that combines internal R&amp;D programs with strategic partnerships across the biotech and pharmaceutical ecosystem. This approach enables the enhancement of both existing and next-generation assets, including antibody-drug conjugates (ADCs), radiopharmaceuticals, and other complex biologics, transforming therapies traditionally used in later lines into safer, more effective first-line treatment options.&#34;Our focus is clear: solve drug delivery at the cellular level so cancer therapies, whether developed by Defence or by our partners, can reach their full potential,&#34; said Sébastien Plouffe, CEO of Defence Therapeutics. &#34;Accum® is designed to create optimal value for partners while ultimately delivering better outcomes for patients.&#34;With this refined positioning, Defence Therapeutics reinforces its commitment to precision oncology, collaboration, and translating cutting-edge science into life-changing treatments, with a business model designed to generate scalable value for partners and long-term value for shareholders. To learn more or explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information: Sebastien Plouffe CEO, Founder and Director P: (514) 947-2272 Splouffe@defencetherapeutics.com www.defencetherapeutics.comCautionary Statement Regarding &#34;Forward-Looking&#34; InformationThis release includes certain statements that may be deemed &#34;forward-looking statements&#34;. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects&#34;, &#34;plans&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;projects&#34;, &#34;potential&#34; and similar expressions, or that events or conditions &#34;will&#34;, &#34;would&#34;, &#34;may&#34;, &#34;could&#34; or &#34;should&#34; occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.<img id="corporateNewsLogo" src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg"/>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280931<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280931/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280931/375"/></article></div>

Defence Therapeutics Inc. has announced a strategic shift to focus on its Accum® precision drug-delivery platform, aimed at enhancing the effectiveness of cancer biologics. The company plans to advance this platform through internal development and strategic partnerships, targeting improved therapeutic potency and reduced toxicity. CEO Sébastien Plouffe emphasized the goal of optimizing drug delivery to maximize treatment outcomes for patients. This refined strategy underscores Defence's commitment to precision oncology and collaboration within the biotech ecosystem, aiming to deliver transformative therapies to patients.

StockTitan

VG Health

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

ESC NEUBASE THERAPEUTI

Black Diamond Therapeutics

iShares US Pharma

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

SPDR S&P Biotech

VanEck Biotech ETF

Turn Therapeutics

Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics | DTCFF Stock News